|
|
|
|
Problems swallowing solid food and weight loss may be a sign of cancer of the esophagus. more...   |
 In Trials: Treatments for Rheumatoid Arthritis Peter Barland, M.D. With the help of new drugs such as Enbrel and Remicade, so-called TNF alpha blockers, many rheumatoid arthritis (RA) sufferers have seen a dramatic improvement in their symptoms. Approximately one-third of patients even achieve long-standing remission of their disease. But for some RA sufferers, the anti-TNF drugs are not effective.1 Thus, there is clearly a need for additional agents to treat RA. Two new drugs, rituximab and abatacept, have recently been tested in Phase II trials and appear to provide effective alternatives. Rituximab (RTX) Rituximab (RTX) is an antibody directed against a membrane protein, CD20, that is found on cells that are involved in the joint inflammation that is responsible for the symptoms of rheumatoid arthritis. Two large, prospective, double-blind, placebo-controlled trials have recently reported that RTX is effective in the treatment of RA patients. In one trial, 40% of the patients given RTX and methotrexate, an older drug for the treatment of the disease, achieved a 50% improvement in their symptoms compared with 13% in another group that received methotrexate alone. Abatacept The second drug in trial, abatacept, is a human protein manufactured through advanced genetic techniques. Abatacept competes with naturally occurring so-called proinflammatory proteins. These proteins promote inflammation and block the activation of T cells thought to be involved in the inflammatory reaction characteristic of rheumatoid arthritis. In two large double-blind studies involving nearly 700 people, a statistically significant improvement in physical function was seen in the group given abatacept. It should be noted that there have been several reports of serious and unusual infections seen in patients treated with abatacept, so if this drug is approved it will probably be with a caution concerning the possibility of infection and that it not be used together with other immunosuppressive drugs. References 1. Wendling D. et al. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone spine 2005;72:309-312. return 2. Edwards JCW et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-2581. 3. Van Vollenhoven R. et al. Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis (RA): results from the dose-ranging assessment international clinical evaluation of rituximab in RA (DANCER) study. Annual European Congress of Rheumatology (EULAR). 2005;Abst SAT0072. Ann Rheum Dis. 2005;64(suppl 3):432. 4. Genovese MC et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor inhibition. N Engl J Med 2005;353:1114-1123. 5. Kremer JM et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-2271. October, 2005 | ||
 |
Email this article to a friend |
|
|
|
NEWS SEARCH CONTENTS MEDITORIAL ASK DISCUSS REGISTER HELP HOME |
|||
© 2008 interMDnet Corporation. All Rights Reserved. PRIVACY POLICY |
|||